Search

Psoriasis is a chronic inflammatory disease that affects quality of life and has systemic repercussions as it is associated with several comorbidities, for which reason we have an extensive range of therapeutic resources, including topical agents, phototherapy, classic systemic drugs and emerging biological treatments. One or another treatment will be indicated depending on severity and other factors associated with the patient and the illness. Biological agents have revolutionised the treatment of moderate to severe psoriasis, offering high rates of effectiveness and safety for patients, so improving their quality of life. Tildrakizumab is a new approved by the EMA biological agent, part of a group of drugs with a mechanism of action based on the inhibition of interleukin-23. [ABSTRACT FROM AUTHOR]

Copyright of Acta Pediátrica Española is the property of Ediciones Mayo and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)